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EvolutionThe human apolipoprotein B mRNA editing enzyme catalytic peptide-like 3 (APOBEC3; A3) family of proteins
(A3A-H) are known to restrict various retroviruses and retroelements, but the full complement of rhesus
macaque A3 proteins remains unclear.We report the isolation and characterization of the hA3Ahomologue from
rhesus macaques (rhA3A) and show that the rhesus macaque and human A3 genes are orthologous. RhA3A is
expressed at high levels in activated CD4+ T cells, is widely expressed inmacaque tissues, and is degraded in the
presence of the human immunodeﬁciency virus (HIV-1) and simian–human immunodeﬁciency virus (SHIV)
genomes. Our results indicate that rhA3A is a potent inhibitor of SHIVΔvif and to a lesser extent HIV-1Δvif. Unlike
hA3A, rhA3A did not inhibit adeno-associated virus 2 (AAV-2) replication and L1 retrotransposition. These data
suggest an evolutionary switch in primate A3A virus speciﬁcity and provide the ﬁrst evidence that a primate A3A
can inhibit lentivirus replication.edicine, University of Colorado
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In the last decade several host restriction factors havebeendiscovered
that can restrict the replication of HIV-1. One of these restriction factors,
Apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (APOBEC3;
A3), has been shown to inhibit a wide range of retroviruses and other
viruses such as the parvoviruses, papillomaviruses, and hepadnaviruses
(Abe et al., 2009; Baumert et al., 2007; Bonvin and Greeve, 2007; Bonvin
et al., 2006; Chen et al., 2006; Henry et al., 2009; Jarmuz et al., 2002; Köck
andBlum, 2008;Mahieux et al., 2005;Narvaiza et al., 2009;Noguchi et al.,
2007; Paprotkaet al., 2010; Sheehyet al., 2002; Strebel, 2005; Turelli et al.,
2004; Vartanian et al., 2008; Zhang et al., 2008). A3 proteins comprise a
family of seven cytidine deaminases (A3A, A3B, A3C, A3D, A3F, A3G, and
A3H) that catalyze the deamination of cytidine to uracil on single-
stranded DNA or RNA through a highly conserved Zn+2-binding motif
(C/H-X-E-X23–28-P-C-X2–4-C) (Chiu and Greene, 2009; Goila-Gaur and
Strebel, 2008; Huthoff andMalim, 2005; Yu et al., 2004). These proteinsalso containakeyglutamate required forproton shuttlingduring catalysis
and two aromatic amino acids residues required for RNA substrate
binding (Jarmuz et al., 2002).
The A3 proteins can be divided into those with a single (A3A,
A3C, A3H) or double (A3B, A3D, A3F, and A3G) cytidine deaminase
domains (CDA). The double CDA proteins A3D, A3F, and A3G have
been shown to restrict the replication of HIV-1 isolates that do not
express a functional Vif protein while A3B could inhibit HIV-1
independent of Vif (Dang et al., 2006; Doehle et al., 2005; Kao et al.,
2003; Liddament et al., 2004; Sheehy et al., 2002; Smith and Pathak,
2010; Wiegand et al., 2004; Yu et al., 2004; Zheng et al., 2004). The
Vif protein is known to bind to select A3 proteins and shunt the A3
proteins to the proteasome for degradation (Liu et al., 2004; Marin
et al., 2003; Mehle et al., 2004; Sheehy et al., 2003; Yu et al., 2003).
Mutagenesis studies have shown that the N-terminal CDA lacks
catalytic activity and is responsible for binding the RNA while the
C-terminal CDA mediates sequence-speciﬁc deamination of single-
stranded DNA (Yu et al., 2004). In addition to deaminase dependent
functions, hA3G and hA3F inhibit virus replication by deaminase-
independent mechanisms (Holmes et al., 2007a,b). Human A3G
(hA3G) and hA3F can also inhibit DNA synthesis, which may
involve interference of t-RNA Lys3 primer annealing, initiation and
elongation of DNA synthesis and minus or plus strand DNA
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2007a; Iwatani et al., 2007; Li et al., 2007; Luo et al., 2007; Newman
et al., 2005; Ooms et al., 2010). Of the single CDA A3 proteins, hA3A
has no activity against HIV-1 while hA3C can be incorporated into
virions but only has weak activity against HIV-1 and foamy virus
(Langlois et al., 2005; Perkovic et al., 2009). Human A3H is now
known to have seven haplotypes, several of which can be stably
expressed (Harari et al., 2009; Ooms et al., 2010; Wang et al., 2011).
However, attempts to detect hA3H in isolated peripheral blood
mononuclear cells (PBMC) have been unsuccessful (Li et al., 2010).
Previous research has shown that human APOBEC3A (hA3A) lacks
antiviral activity against HIV-1, but inhibits the replication of adeno-
associated virus 2 (AAV-2), intracisternal A particles (IAP), and long
interspersed nuclear element 1 (L1) (Bogerd et al., 2006a,b; Chen et al.,
2006; Muckenfuss et al., 2006). Although hA3A contains one CDA, the
deaminase activity of hA3A is not required for its inhibitory role against
AAV or retrotransposons, suggesting that a deaminase-independent
mechanismof inhibition is occurring (Narvaiza et al., 2009).HumanA3A
also contains signiﬁcant homology to the N-terminal half of hA3G, does
not associate with the viral nucleocapsid complex (NPC) of HIV-1 but is
readily incorporated into virions (Goila-Gaur et al., 2007).
Simian immunodeﬁciency (SIV) and simian–human immunodeﬁ-
ciency (SHIV) viruses have been invaluablemodels for studying various
aspects of HIV-1 pathogenesis. Sequencing of the rhesus macaque
genome has led to the identiﬁcation of rhesus homologues of A3B, A3C,
A3D, A3F, A3G and A3H. Here we describe the identiﬁcation of an A3A
homologue in rhesus macaques (rhA3A) and present evidence that the
human andmacaque Apobec3 genes are orthologous.We show that the
rhA3A protein is expressed well in activated macaque CD4+ T cells and
other rhesus macaque tissues, is incorporated into virions, is degraded
by both HIV-1 and SHIV in a Vif dependent manner, and restricts the
replication of SHIV (expressing the SIVmac239 Vif) and HIV-1.
Results
Molecular cloning of rhesus macaque A3A
Humans encode seven APOBEC3 (hA3) genes that are tandemly
arrayed on chromosome22, but there is uncertainty onwhether a similar
arrayof rhA3genes is expressed in the syntenic regionon rhesusmacaque
chromosome 10. In particular, no rhA3A gene has been cloned from
rhesusmacaques suggesting that this genemay have been deleted in the
genome of this primate species (OhAinle et al., 2008; Virgen and
Hatziioannou, 2007). However, a recent study showed that A3A is
encoded in the genome of several monkey species, including African
green and owl monkeys (Bulliard et al., 2011). The evolutionary
conservation of A3A therefore suggested that the rhA3A genewasmissed
in previous cloning attempts. To determine whether rhA3A is expressed,
we took advantage of the sequencing of the rhesus macaque genome
(Rhesus Macaque Genome Sequencing and Analysis Consortium, 2007).
BLAST analysis of the hA3A sequence revealed that the ﬁrst exon has a
counterpart on the rhesus macaque chromosome 10, thus providing a
potential forward primer for PCR ampliﬁcation. However, counterparts of
other hA3A exons were not detected in the rhesus macaque genome
immediately downstream of this putative exon 1 sequence. Thus, the last
exon of hA3Awas used as a reverse primer.
Human A3A is not expressed in resting peripheral blood mononu-
clear cells (PBMC), but is substantially induced by cellular activation and
cytokines (Koning et al., 2009; Refsland et al., 2010). We therefore
utilized cDNA fromConcanavalin A-activated rhesusmacaque PBMCs in
an attempt to detect rhA3A. A dominant band of the correct size was
ampliﬁed in the ﬁrst attempt by PCR. BLAST analysis of the cloned
amplicon revealed 89% nucleotide identity with hA3A. Alignment of the
amino acid sequence with recently identiﬁed A3A sequences showed
the highest identity (90%) with A3A from African green monkeys,
which, together with Asian macaques, are considered as “Old World”monkeys (Fig. 1A). This alignment also revealed primate lineage-
speciﬁc insertions/deletions (indels). In particular, we observed de-
letions at positions 27 to 29 in the hominid A3A genes. To further explore
the clustering of A3A sequences with speciﬁc primate lineages, we
constructed a phylogenetic tree that excluded the contribution of indels.
As shown in Fig. 1B, A3A sequences clustered accordingly with their
corresponding primate taxons. These analyses demonstrate that the
cloned rhA3A gene is a bona ﬁdemember of the A3A gene family.
Evidence that seven A3 genes are tandemly arrayed on chromosome 10
of rhesus macaques
While the sequence of the rhesus macaque genome has been
“completed,” it still remains unclear why this did not reveal the rhA3A
gene. We attempted to determine the position of the cloned rhA3A
sequence in relation with other rhA3 genes. At the time that the
analyses were performed, only the nucleotide sequences for rhesus
macaque rhA3C, rhA3F, rhA3G and rhA3H had been deposited into
GenBank. BLAST analysis of these cDNA sequences against the rhesus
macaque genome revealed their distinct positions as shown in Fig. 2A.
The position of rhesus macaque rhA3B and rhA3D remains unknown,
although their amino acid sequences were published (Virgen and
Hatziioannou, 2007). We ﬁrst attempted to determine the relative
positions of rhA3B and rhA3D in chromosome 10 based solely on the
genome sequence. Using the geneid program (http://genome.crg.es/
geneid.html), genome sequences between rhA3C and rhA3F predicted
rhA3D (Fig. S1), while genomic and previously unlocalized sequences
upstream of rhA3C predicted rhA3B (Fig. S2).
The relative placement of rhA3B and rhA3D in the rhesus macaque
genome suggested a similar A3 gene organization as found in humans,
with the notable uncertainty of rhA3A. We therefore focused on genomic
sequences immediately upstream of rhA3B. BLAST analysis of the cloned
rhA3A sequence revealed an identical sequence corresponding to rhA3A
exon 1 in the genome. This putative rhA3A exon 1 was immediately
followedby560 bpofCT-rich repeat sequences and16.8 kbof unresolved
sequence. It is possible that these repeat sequences interfered with
accurate sequencing of this region. On the other hand, exons 2 to 4 of
rhA3A mapped to an unlocalized chromosome 10 genomic scaffold
sequence with GenBank Accession NW_001096321.1. The 3764 bp
NW_001096321.1 sequence could easily be accommodated in the
16.8 kb genomic gap. Notably, theNW_001096321.1 sequence contained
838 bp of intron sequence upstreamof exon 2.We therefore investigated
whether the NW_001096321.1 links directly with the genome by
amplifying rhesus macaque genomic DNA with primers designed in
exon 1 and 2 of rhA3A (Fig. 2A). Direct sequencing of the 1.8-kb amplicon
revealed identitywith theﬂanking sequences following theputative exon
1 in the genome and prior to exon 2 in NW_001096321.1 (Fig. 2A). These
results provide strong evidence that rhA3A is likely encoded in the rhesus
macaquegenome immediatelyupstreamof rhA3B. Overall, these analyses
suggest that the seven rhA3members are tandemly arrayed in the rhesus
macaque genome, similar to humans.
The rhesus macaque and human A3 genes are orthologous
Rodents encode a singleA3 gene, while humans encode seven. Other
mammals, such as dogs, pigs, horses and sheep encode a variety of A3
genes that reveal substantial duplication, unequal cross-over and
divergent evolutionof individualmembers andare therefore considered
paralogues (Conticello et al., 2005; LaRue et al., 2009). This pattern of
“evolutionary shufﬂing” could be roughly inferred in phylogenetic trees,
where A3 segments containing the canonical deoxycytidine deaminase
motif can be classiﬁed into Z1, Z2 and Z3 clades (LaRue et al., 2009). To
extend this classiﬁcation to rhA3 genes, a phylogenetic tree comparing
the human, rodent and rhesus macaque A3 amino acid sequences was
constructed (Fig. 2B). The rhA3 genes consistently clustered with the
hA3 counterparts (Fig. 2B). Thus, each of the seven rhesusmacaque and
Fig. 1. Sequence analysis of the rhA3Aproteins. Panel A. Protein sequence alignment of primate A3Aproteins. Dashes correspond to indels, while residues highlighted in pink or orange are
conservedormatched the consensus, respectively. Some indelswere associatedwith speciﬁc primate taxons. This includes a hominid-speciﬁc deletion at amino acidpositions 27 to 29, and
a deletion in residues 108–109 in NewWorld monkeys. Panel B. A3A phylogeny. The amino acid sequence alignment was subjected to phylogenetic analyses using the neighbor joining
method, excluding sequence gaps, and rooted using the C-terminal half of rhesus macaque A3G as an outgroup. Numbers correspond to the percentage of clustering following 1000
subreplicates. RhA3A clustered most signiﬁcantly with A3A from another Old World monkey species, African Green monkey (AGM).
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indicating that the genes are orthologous. In other words, we found
no evidence for signiﬁcant “shufﬂing events” in the A3 locus after the
evolutionary split between monkeys and humans.
Expression of rhA3 genes in rhesus macaque tissues and activated CD4+
T cells
We next determined rhA3A mRNA expression in various perfused
rhesusmacaque organs and tissues. Speciﬁc rhA3A primerswere used to
determine expression in 14 visceral organs and 12 regions of the centralnervous system (CNS) by RT-PCR. GAPDH was used to assess the
integrity of RNA in the samples (data not shown). Our results indicate
that rhA3Awas not onlywidely expressed in the visceral organs but also
in different regions of the CNS (Fig. 3A).We veriﬁed the speciﬁcity of the
rhA3A ampliﬁcation by directly sequencing the PCR amplicons (data not
shown). Extensive detection of rhA3A in various lymphoid organs raised
the possibility that rhA3A may also be expressed in CD4+ T cells, a
primary cellular target of SHIV and SIV infection in vivo.
To determine the relative expression of rhA3A against other rhA3
members, we developed Taqman-based real-time PCR assays to
speciﬁcally quantify each of the seven rhA3 genes (Table 1). To evaluate
Fig. 2. Sequence characterization of the rhesusmacaqueA3 locus. Panel A. Genome organization of rhesusmacaque A3 genes. (Top) Published cDNA sequences for rhA3C, rhA3F, rhA3G and
rhA3Hwere subjected to BLAST analysis against the rhesus macaque genome. Matching exons were plotted against assigned genome coordinates, shown here in 20 kb intervals. *RhA3B
and rhA3DEwere predicted by subjecting the genome sequences upstream of rhA3C or ﬂanked by rhA3C and rhA3F to the geneid prediction program (http://genome.crg.es/geneid.html),
respectively. RhA3A ampliﬁed from activated PBMCs was subjected to BLAST analysis. RhA3A exon 1 mapped in the genome directly upstream of A3B, but this was followed by 16.8 kb of
unresolved sequence (dotted lines). (Bottom) A3A exons 2 to 4 matched sequences from an unlocalized chromosome 10 genomic scaffold sequence. Primers based on A3A exons 1 and 2
ampliﬁeda 1.8 kbproduct thatmatchedﬂanking sequences after exon1 in the genomeandbefore exon2 in theunlocalized genomic scaffold (gray lines). This provides strongevidence for
the current placement of rhA3A in the rhesusmacaque genome. Panel B. Phylogeny of rhesusmacaque and humanA3proteins. Amino acid sequences from rhesusmacaque and humanA3
geneswere aligned,with thedouble-CDAmembers split into anN- andC-terminal half. For example, A3B-C corresponds to the C-terminal half ofA3B. RhA3A clusteredwith theC-terminal
half of A3B and A3G, forming the Z1 clade. Each rhesus macaque A3 gene clustered signiﬁcantly with the corresponding human A3 gene, suggesting that rhesus macaque and human A3
proteins are orthologous.
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agarose gel electrophoresis whether the primers could amplify other
rhA3 cDNAs. If some cross-reactivitywith the primerswas observed, we
subjected 108 rhA3 cDNA copies in a real-time PCR reaction that also
includes theprobe. The results of theseanalyses arepresented inTable2.
Most of the assays developed did not cross-react with other A3 family
members. In those instanceswhere some cross-reactivitywas observed,
detection of similar A3members was least 104 fold lower in magnitude
than what would be expected for the gene of interest. Thus, the real-
time PCRmethods could be used to distinguish the relative levels of the
individual A3members.Rhesus macaque PBMCs from three uninfected donors were
stimulated with Staphylococcal Enterotoxin B (SEB), previously
determined to beapotent activator of rhesusmacaque T cells (Kakimoto
et al., 1999). However, SEB-stimulation still did not result in consistent
activation, since the levels of CD25 expression in CD4+ T cells varied
between the 3 donors (Fig. 3B; upper panel A). Total RNAwas extracted
from magnetically puriﬁed CD4+ T cells from these activated PBMCs,
and subjected to real-time RT-PCR. Consistent with our failure to clone
rhA3B from activated PBMCs, rhA3B mRNA was not detected in any
donor (Fig. 3B; lower panel). With one exception (rhA3A donor 3), the
expression of individual rhA3 genes between the donors did not vary
Fig. 3. Expressionof rhA3A in rhesusmacaque tissuesandCD4+Tcells. PanelA.RhA3A expressionproﬁle invisceralorgansand theCNS.Multiple tissueswereobtained fromanSIVnegative
macaque. RNA from these tissues was analyzed for the presence of rhA3AmRNA by RT-PCR. Amplicons were run on 1.5% agarose gels and visualized by staining with ethidium bromide.
Ampliconswere directly sequenced and found to correspond to rhA3A. All sampleswere positive for GAPDHRNA to control for integrity of RNA in the samples (data not shown).Upper gel,
rhA3AmRNA from14visceral organs. Lower gel, rhA3AmRNA from12 regions of the central nervous system. The sizemarkers (in base pairs) are shown to the left. Panel B. Expression ofA3
genes in rhesusmacaque CD4+ T cells.Upper, Activation of rhesus CD4+ T cells. Rhesusmacaque PBMCswere activatedwith 2.5 μg/ml SEB overnight, and subjected to FACS analysis. FACS
histograms of CD25expression inCD3+CD4+ cells before (resting; blue) and after SEB activation (activated; red) are shown. CD4+T cellsweremagnetically puriﬁedbynegative selection,
andRNAwas extracted for quantitative RT-PCR analyses. Lower, rhA3mRNA levels in activated rhesusmacaqueCD4+T cells.A3 cDNAwas subjected to real-timequantitative RT-PCRusing
primers speciﬁc for individual rhA3 genes (Table 1). Dashed lines correspond to the assay limit of detection (5 input copies/reaction), while error bars correspond to standard deviations
from triplicate determinations.
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expression levels. Since rhA3G is well accepted as a biologically relevant
restriction factor against SIV (Schmitt et al., 2009, 2010; Schröfelbauer etal., 2006; Sui et al., 2010), we compared the expression of other rhA3
genes relative to rhA3G. Setting the average rhA3G level from the 3
donors as 1, only rhA3A (excluding donor 3), rhA3C and rhA3H exhibited
Table 1
Rhesus macaque A3 real-time PCR primers and probes.
Apobec3 Primersa Primer size
(nt)
PCR product
(nt)
Ta
(°C)
RhA3A Forward: CAAGGCTAAGAATGTTCCCT 20 201 59
Reverse: ATGCGCAGTCTCACGTGTTT 20
Probe: [6-FAM]TGAGGTTCCTTCTTGGCAGT[TAMRA-6~FAM] 20
RhA3B Forward: TGGGGTAGAGATTGGCAGAG 20 224 59
Reverse: TTGGAAGTGAACGTGTCTGG 20
Probe: [6-FAM]CCGCATGCTAAAGGAGATTC[TAMRA-6~FAM] 20
RhA3C Forward: AGGTGCTTCCTCTCCTGGTT 20 197 59
Reverse: CCCTGCTGGTAATTCGGATA 20
Probe: [6-FAM]GGCACAACAATGTGATGCTC[TAMRA-6~FAM] 20
RhA3D Forward: GTCTTCCGAAACCAGGTTGA 20 245 59
Reverse: AGCCCCTCCTGGTAATCTGT 20
Probe: [6-FAM]CTCTTGGTTCTGCGACAACA[TAMRA-6~FAM] 20
RhA3F Forward: GAAGGTGGCCGAATTCCTA 19 264 60
Reverse: TTTCTGAGAATCTCCTTTAGCTTGT 25
Probe:[6-FAM]ACTGGGAAACAGATTATCGCA[TAMRA-6~FAM] 21
RhA3G Forward: GCCATTTAAGCCTTGGAACA 20 230 60.5
Reverse: GAGCCTGGTTGCGTAGAAAG 20
Probe: [6-FAM]AACCTTGGGTCAGTGGACAG[TAMRA-6~FAM] 20
RhA3H Forward: AAGGACCATGCAGAAATTCG 20 239 59
Reverse: ACCTGGGATCCACACAGAAG 20
Probe: [6-FAM]AACTATCAGGAGGGGCTGCT[TAMRA-6~FAM] 20
a PCR conditions were as follows: 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and the corresponding annealing temperature (Ta) for 45 s.
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that of rhA3G. In contrast, rhA3F and rhA3Dwereonaverage expressed at
2.4- and 13.6-fold lower than rhA3G, respectively. Thus, rhA3A, rhA3C
and rhA3H mRNAs are expressed to similar levels as rhA3G in SEB-
activated rhesus macaque CD4+ T cells.
Nucleocytoplasmic localization of HA-tagged rhA3A
Previous studies have shown that the cytoplasmic localization of
hA3G and the nucleocytoplasmic localization of hA3A could partially
explain the differences in the range of retroviruses or retrotransposons
that were inhibited by these proteins (Bogerd et al., 2006a,b; Chen et al.,
2006; Goila-Gaur et al., 2007; Muckenfuss et al., 2006). To determine
whether rhA3A exhibited a similar subcellular localization, we generated
amolecular clone of rhA3Awith anHA-tag at the amino terminal end for
detectionpurposes. Aplasmidexpressingeither rhA3Gor rhA3A(Fig. 4A)
was transfected into 293 cells and the expression examined by Western
blot analysis using an antibody directed against the HA tag. As shown in
Fig. 4A, 293 cells transfectedwith the vector expressing rhA3G expressed
a protein with an Mr of 45kD while cells transfected with the vector
expressing rhA3A expressed a proteinwith anMr of 24kD, which reﬂects
the size of the two different proteins (363 amino acids for rhA3G versus
202 amino acids for rhA3A). Using confocal microscopy, we found that
rhA3G was observed exclusively in the cytoplasm (Figs. 4B–D) and that
rhA3A was detected in both the cytoplasm and nucleus as it co-localized
with a nuclear marker (Figs. 4E–G). Similar to other studies, hA3A wasTable 2
Speciﬁcity evaluation of rhApobec3 primers and probes.
Primer-
probe
set
Template cross-reactivity (input: 5×108 copies)
RhA3A RhA3Ba RhA3C RhA3Da RhA3F RhA3G RhA3H
RhA3A NT — NT 9.9×101 2.7×103 —
RhA3B — — 2.0×103 — — —
RhA3C — NT NT — — 1.5×104
RhA3D — 1.5×102 — — — —
RhA3F 6.5×103 NT — NT 3.4×101 —
RhA3G — NT — NT 5.1×104 —
RhA3H — NT 1.7×103 NT — —
a RhA3B (340nt) and rhA3D (370nt) templates were synthetic oligos based on
predicted sequences. —, no cross-reactivity observed based on endpoint-PCR and gel
electrophoresis; NT: not tested.observed rhA3A in both the nucleus and cytoplasm (Figs. 4H–J). Thus any
differences in the retroviral restriction properties of hA3A and rhA3A
could not be explained by the subcellular localization.
Minimal inhibition of foreign DNA reporter gene expression by rhA3A
and hA3A
In a recent study, hA3A was shown to inhibit the expression of
transfected plasmid DNA by deamination of the incoming plasmid DNA
(Stenglein et al., 2010). Co-transfection of an eGFP reporter plasmid
with hA3A in 293 cells resulted in approximately 20% reduction in the
number of cells expressing eGFP signal 2 days. In these investigators'
model, the incoming DNA induces an interferon-induced up-regulation
of hA3A expression, the cytidine residues are deaminated resulting in
uracils, which are excised by UNG2. This will eventually result in
cleavage and degradation of the DNA backbone (Stenglein et al., 2010).
This phenomenon could signiﬁcantly confound experiments that
involve co-transfection of A3A with viral plasmid constructs.
Since our virus experiments involving rhA3A or hA3A lasted no
longer than 48 h, we determined whether rhA3A, hA3A or rhA3G
interfered with the expression of enhanced green ﬂuorescent protein
(eGFP) from a foreign plasmid. Plasmids expressing either rhA3A,
hA3A or rhA3G were co-transfected into 293 cells 24 h prior to
transfection with the plasmid expressing eGFP under the control of
the CMV promoter. At 2 days post-transfection of eGFP, the cells were
analyzed for ﬂuorescence by ﬂow cytometry. We detected 14.1, 14.5,
11.2, and 14.6% eGFP positive cells in the presence of empty vector,
rhA3A, hA3A, or rhA3G, respectively (Fig. 5A). These results indicate
that hA3A had minimal impact (b20%) while rhA3A had no impact on
reporter gene expression from foreign plasmids at 48 h.
Human and rhesus macaque A3A does not inhibit SHIV or HIV-1
production in 293 cells
It can be argued that the slight inhibition of plasmid reporter gene
expression by hA3A may be ampliﬁed with typically longer plasmids
containing a full-length viral genome. Similarly, the absence of an effect
by rhA3A in plasmid reporter expression may be enhanced in the
context of a full-length viralmolecular clone.Weconjectured that if A3A
can degrade viral infectious molecular clones, then virus production
would be signiﬁcantly inhibited. We therefore investigated whether
47.5 
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Fig. 4. Expression of an HA-tagged rhA3A. Panel A. 293 cells were transfected with 1.5 μg HA-tagged rhA3A, rhA3G, or the empty expression vectors. At 48 h, cells were lysed and
proteins separated by SDS-PAGE and analyzed by Western blot using an antibody directed against the HA-tag. Sizes of the molecular standards are to the right. RhA3A migrates at
about half the molecular weight than rhA3G, consistent with their amino acid sequences. Panel B-J. Subcellular localization of rhA3G, hA3A, and rhA3A. 293 cells were transfected
with HA-tagged vectors expressing rhA3A, hA3A, or rhA3G and a vector expressing an eGFP tagged nuclear marker (___, Clontech). At 48 h, cells were ﬁxed and stained with anti-HA
for 1 h, washed and detected using a horse anti-rabbit-Ig Cy5 antibody. Cells were examined under a Nikon A1 ﬂuorescent microscope andmicrographs taken using a 100× objective
with a 2× digital zoom using the E2-C1 software package as described in the Materials and methods.
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293 cells were transfected with the plasmids expressing hA3A, rhA3A,
rhA3G or the empty plasmid 24 h prior to transfection with plasmids
with the SHIVΔvif or HIV-1Δvif constructs. At 2 days post-transfection
with the viral genomes, the culture mediumwas assayed for either p27(SHIV) or p24 (HIV-1). We did not observe a signiﬁcant decrease in the
level of SHIVΔvif p27 released into the culture medium in cells co-
transfected with empty vector, rhA3A, hA3A, or rhA3G at 2 days post-
transfection (Fig. 5B). Similar ﬁndings were observed for HIV-1Δvif
(Fig. 5C). These data suggest that rhA3A and hA3A likely have no post-
31K. Schmitt et al. / Virology 419 (2011) 24–42entry restriction activity against SHIV or HIV-1 and reinforce the
conclusion that rhA3A and hA3A haveminimal impact on plasmid DNA
stability at 2 days post-transfection. Thus, our subsequent experiments,
which involve analyzing cells within 48 h, should not be inﬂuenced by
potential plasmid-speciﬁc restriction.
Rhesus macaque A3A inhibits the infectivity of SHIVΔvif and HIV-1Δvif
We next determined if rhA3A could inhibit the infectivity of SHIV
and SHIVΔvif. For comparison, we also co-transfected these viral
constructs with plasmids expressing rhA3G, rhA3C, or hA3A. Virion
infectivitywasmeasured by taking the ratio of infectious titer in TZM-bl20
80
60
40
100
0
%
 p
27
 re
le
as
ed
 c
om
pa
re
d 
to
 th
e
pc
DN
A3
.1
(+)
 co
nt
ro
l 
120
 
 
 
 
pcDNA3.1(+) rhA3G rhA3A hA3A 
0
10
15
20
5
 
pcDNA3.1(+) 
 
 
 
rhA3A hA3A rhA3G 
%
 E
G
FP
 p
os
iti
ve
 c
el
ls
 
110
20
80
60
40
100
0
%
 p
24
 re
le
as
ed
 c
om
pa
re
d 
to
 th
e
pc
DN
A3
.1
(+)
 co
nt
ro
l 
 
 
 
 
pcDNA3.1(+) rhA3G rhA3A hA3A 
A
C
Bcells and comparing to thewild-type SHIV construct co-transfectedwith
empty vector control. Our results indicate that rhA3A and rhA3G
reduced the level of infectious SHIVΔvif nearly 20-fold compared to the
parental SHIV, while hA3A reduced the infectivity of SHIVΔvif
approximately 10-fold (Fig. 6A). In contrast, rhA3C did not inhibit the
level of infectious virus released from cells. SHIV virions produced in the
presence of rhA3A, hA3A or rhA3G were puriﬁed and concentrated by
ultracentrifugation and analyzed by Western blot. Consistent with the
virion infectivity data, rhA3A was incorporated into SHIVΔvif and to a
lesser extent in SHIV (Fig. 6B). However, wewere unable to detect hA3A
in either SHIV or SHIVΔvif virions.
We also tested whether rhA3A had activity against HIV-1. HIV-1
(NL4-3) and HIV-1Δvif constructs were co-transfected with plasmids
expressing rhA3A, hA3A, or hA3G. Consistent with previous reports,
hA3A did not inhibit infectivity of HIV-1Δvif virions, while hA3G
reduced HIV-1Δvif virion infectivity by 10-fold. Surprisingly, rhA3A
reducedHIV-1Δvif virion infectivity approximately 3-fold (Fig. 6C). HIV-
1 virions released from293 cells expressing either hA3G, hA3Aor rhA3A
werepartially puriﬁed by ultracentrifugation. The resulting virionswere
analyzed by Western blot using an anti-HA antibody. Consistent with
previously published data, hA3A was detected in both HIV-1 and
HIVΔvif virions. However, rhA3Awas not detected in HIV-1 andHIVΔvif
virions (Fig. 6D). Together, these ﬁndings indicate that unlike hA3A,
rhA3A reduces the infectivity of both SHIVΔvif and HIV-1Δvif.
Deletion of amino acids 27–29 of rhA3A abolishes its anti-viral activity
Hominid andmonkey A3As can be distinguished by a 3 amino-acid
indel between residues 27 to 29. We hypothesize that this region may
contribute to the differential activity of rhA3A and hA3A against
SHIVΔvif and HIV-1Δvif. To test this hypothesis, we constructed a
rhA3A mutant in which amino acids 27–29 (SVR) were deleted. The
resultingmutant, rhA3AΔSVR, was found to be stable in cells (data not
shown). Interestingly, rhA3AΔSVR was inactive against SHIVΔvif
(Fig. 7A) and HIV-1Δvif (Fig. 7B). These ﬁndings suggested that these
monkey-speciﬁc A3A residues were critical for lentivirus inhibition,
but was functionally lost in the hominid lineage.
RhA3A, but not hA3A, is sensitive to SIV and HIV-1 Vif-mediated degradation
We next determined the stability of rhA3A and hA3A in the
presence of the SHIV, SHIVΔvif, HIV-1, or HIVΔvif genomes. Each full
length molecular clone was co-transfected into 293 cells along withFig. 5.Minimal restrictionof foreignDNAby rhA3A andhA3A. Panel A. Expression constructs
(3 μg) of HA-tagged rhA3A, hA3A and rhA3Gwere ﬁrst transfected into 293 cells for 24 h. At
24 h post-transfection, the 293 cells were re-transfected with a plasmid encoding a CMV-
driven eGFP reporter and assayed for reporter expression. The cells were removed from the
plate and ﬁxed. All samples were analyzed by a ﬂow cytometer and the mean ﬂuorescence
intensity (MFI) for eGFP positive cells was calculated. The MFI ratio and percentage of eGFP
cells were calculated for each samples and the experiment was run in triplicate. All groups
were compared to the pcDNA3.1(+) plus EGFP control using a Student's t-test with pb0.05
considered signiﬁcant. Panel B. SHIVΔVif production in the presence of rhA3A, hA3A and
rhA3G. Cells were ﬁrst transfected with 0.5 μg of plasmids expressing HA-tagged rhA3A,
hA3A, rhA3G or empty vector. At 24 h post-transfection, the 293 cells were re-transfected
with a plasmid containing the SHIVΔvif. Virus supernatants were harvested at 2 days post-
transfection with the viral genome. Mean Gag p27 levels as measured using a commercially
available ELISA kit (Zeptometrix) are shown. In all panels, error bars correspond to standard
deviations from triplicate determinations. Panel C. HIV-1Δvif production in the presence of
hA3A and rhA3A. Cells were ﬁrst transfected with 0.5 μg of plasmids expressing HA-tagged
rhA3A, hA3A, rhA3G or empty vector. At 24 h post-transfection, the 293 cells were re-
transfectedwith a 1 μg plasmid containing the HIV-1Δvif. Virus supernatantswere harvested
at 2 days post-transfection with the viral genome. Mean Gag p24 levels as measured using a
commerciallyavailableELISAkit (Zeptometrix)are shown. Inall panels, errorbars correspond
to standard deviations from triplicate determinations.
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Fig. 6. Inhibition of SHIVΔVif and HIVΔVif virion infectivity by rhA3A. Panel A. RhA3A restricts SHIVΔvif. 293 cells were co-transfected with 1 μg wild-type SHIV or SHIVΔvif
molecular clones and 0.5 μg plasmids expressing either empty vector (pcDNA3.1), rhA3A, hA3A, or rhA3G. At 48 h, the culture medium was harvested and virion infectivity
measured by taking the ratio of infectious viral titers on TZM-bl cells. Shown is the percentage virion infectivity with the empty plasmid control normalized to 100%. Panel B. 293
cells were transfectedwithwild-type SHIV or SHIVΔvifmolecular clones and HA-tagged rhA3A, hA3A, or rhA3G. At 48 h, the culturemediumwas collected, clariﬁed by low speed
centrifugation, and concentrated by ultracentrifugation through a 20%/60% (w/v) step-gradient. Each sample was resuspended in 2× sample reducing buffer, boiled, and the
proteins were separated by SDS-PAGE. The presence of rhA3G, hA3A, or rhA3A was detected by Western blot using an antibody directed against the HA-tag (upper) and the
presence of p27 using an antibody directed against p27 (middle). The lower panel are 293 cells transfectedwith vectors expressing rhA3G, hA3A, rhA3A or pcDNA3.1(+) vector in
the absence of the viral genome. Panel C. RhA3A restricts HIV-1Δvif virions. HIV-1 or HIV-1Δvif genomes were co-transfected with HA-tagged hA3A, hA3G or rhA3A as described
for the SHIV experiments in Panel A. Shown is the percentage virion infectivity with the empty plasmid control normalized to 100%. Panel D. Undetectable rhA3A in HIV-1Δvif
virions. Virions were puriﬁed as described for the SHIV experiments in Panel B, and hA3G, hA3A and rhA3A incorporation were detected by Western blot using an anti-HA
antibody, normalizing for Gag p24 levels. The lower panel are 293 cells transfectedwith vectors expressing rhA3G, hA3A, rhA3A or pcDNA3.1(+) vector in the absence of the viral
genome. Mean values in triplicate experiments are shown, and statistical differences with the wild-type control were evaluated using a two-tailed Student's t-test, with pb0.05
(▴) considered signiﬁcant.
32 K. Schmitt et al. / Virology 419 (2011) 24–42plasmids expressing HA-tagged rhA3A, rhA3G, hA3A, or rhA3AΔSVR.
At 24 h, the cells were lysed, proteins precipitated, and analyzed by
Western blot using an antibody speciﬁc to the HA-tag. Our results
show that rhA3G was degraded in the presence of the parental SHIV
but not in cells co-transfected with the SHIVΔvif genome. In contrast,
hA3A was stable in the presence of parental SHIV or SHIVΔvif (the
apparent difference of the hA3A in lanes 4 and 5 is due to less protein
loaded in lane 4). Unlike hA3A, rhA3Awas found to be degraded in thepresence of the SHIV genome but stable in the presence of the
SHIVΔvif genome (Fig. 8A). These results again suggest that rhA3A
interacts with the SIV Vif protein. Finally, rhA3A appeared to be less
stable in the presence of the HIV-1 genome and more stable in the
presence of NL4-3Δvif (Fig. 8B). Similar results were observed at 48 h
post-transfection (data not shown). These results suggest that the SIV
and HIV-1 Vif proteins may interact with rhA3A promote its rapid
turnover.
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Fig. 7. Deletion of three amino acids from the N-terminal region of rhA3A abolishes restriction. Panel A. RhA3AΔSVR is inactive against SHIVΔvif. 293 cells were co-transfected with
(1.0 μg) SHIV and SHIVΔvifmolecular clones with vectors expressing (0.5 μg) rhA3A, rhA3AΔSVR, rhA3C, rhA3G or empty vector (pcDNA3.1) in a 12-well plate. At 48 h, the culture
medium was harvested, assessed for p27 and the amount of infectious virus titrated on the TZM.bl cells. Panel B. RhA3AΔSVR is inactive against HIV-1Δvif. 293 cells were co-
transfected with (1.0 μg) HIV-1 and HIV-1Δvif molecular clones with vectors expressing (0.5 μg) rhA3A, rhA3AΔSVR, hA3A, rhA3G or empty vector (pcDNA3.1) in a 12-well plate.
Virion infectivity was calculated normalizing to the wild-type HIV-1 empty vector control. In both panels A and B, the assays were run at least in triplicate. Signiﬁcance in the
restriction was determined with respect to the wild-type empty vector control using a two-tailed Student's t-test (pb0.05; ▴).
33K. Schmitt et al. / Virology 419 (2011) 24–42RhA3A causes low levels of G-to-A mutations in nascent SHIVΔVif
reverse transcripts
RhA3A incorporation into SHIVΔvif virions led to a signiﬁcant
decrease in infectivity (Figs. 6A and B). Our previous study revealed that
rhA3G inhibition of SHIVΔvif virions in target cells was accompanied by
substantial G-to-A mutations (Schmitt et al., 2010). To determine
whether rhA3A has a similar effect, we ampliﬁed a 300 bp region in nef
from target TZM-bl cells and sequenced 15 independent clones.
The results indicate thatwhile rhA3G caused 33 G-to-Amutations in
15 clones (300 bases sequenced in each clone or total of 4500 bp) in the
nef geneof SHIVΔvif,most ofwhich (29)were in the context of 5′-TCT-3′
(Schmitt et al., 2010), while only 7 such mutations were detected withrhA3G hA3A 
SHIV: 
A 
WB:  
β-actin 
WT  ΔVif   WT  ΔVif   WT ΔVif  WT   ΔVif  
rhA3A 
rhA3A 
ΔSVR 
WB: 
αHA 
rhA3G 
rhA3A 
hA3A 
pc
DN
A
H
W
β-
W
α
B
Fig. 8. Sensitivity of rhA3A to lentivirus Vif-mediated degradation. Panel A. SHIV Vif mediates
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co-transfected with rhA3G, hA3A, rhA3A and rhA3AΔSVR. In both panels, the blots were stripprhA3A (Figs. 9A and B). As expected, the corresponding wild-type SHIV
had signiﬁcantly lower G-to-A mutation frequencies (Figs. 9C and D).
These results suggest that while rhA3A and rhA3G appear to have
similar antiviral potency against SHIVΔvif (Fig. 6A), rhA3A produced an
approximately 5-fold decrease in the number of G-to-A mutations in
SHIVΔvif compared to rhA3G.
Rhesus A3A does not inhibit adeno-associated virus 2 (AAV-2)
Previous studies have shown that hA3A can inhibit the replication of
AAV-2 and autonomously replicating parvoviruses (Chen et al., 2006).
We determined if rhA3A could inhibit the replication of AAV-2. 293 cells
were transfected with vectors expressing hA3A, rhA3G, rhA3A or theIV-1: ΔVif  WT    ΔVif WT   ΔVif   WT    ΔVif  WT 
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ed and re-probed with an antibody against β-actin. All assays were performed twice.
34 K. Schmitt et al. / Virology 419 (2011) 24–42empty vector and plasmids expressing AAV-2 and a helper plasmid. At
48 h, the cells were harvested, the extrachromosomal DNA isolated by
Hirt extraction and analyzed using Southern blots for the presence ofrhA3C 
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Fig. 9 (continued).
35K. Schmitt et al. / Virology 419 (2011) 24–42did not signiﬁcantly inhibit AAV-2 replication. A Western blot from an
aliquot of the 293 lysates showed that the A3 proteins were similarly
expressed (Fig. 10B).
RhA3A does not inhibit L1 retrotransposition
L1 elements are autonomous non-LTR retrotransposons that
constitute about 17% of the human genome (Babushok and Kazazian,
2007). L1 elements, through the ORF2 gene product, also facilitate the
retrotransposition of Alu elements, which are present in an additional
11% of the genome. In vitro retrotransposition assays require the co-ssDNA
Double RF
RF (4672 bp)
4306 bp
A B
Fig. 10. RhA3A does not inhibit AAV2 replication. Panel A. Low molecular weight DNA
extracted from 293 cells transfected with recombinant AAV-2 plasmids and either
empty vector (293), hA3A, rhA3A, or rhA3G. A 1% southern blot was run and hybridized
with a
32
P-labeled probe from SSV9 as previously described (Qiu and Pintel, 2002). The
following AAV replication products are shown as dRF (double recombinant form), RF
(recombinant form), and ssDNA. These experiments were performed two times with
the same result. Panel B. A Western blot was performed on an aliquot of the lysate to
show the expression of each A3 protein expressed.transfection of hA3A with L1 plasmids(Rangwala and Kazazian, 2009)
and assaying after 3–4 days, a timepoint where signiﬁcant hA3A
inhibition of plasmid DNA may be observed (Stenglein et al., 2010).
To determine whether rhA3A could inhibit L1 retrotransposition,
we used an L1-eGFP plasmid construct that contains a self-splicing
intron in the opposite orientation within eGFP (pLRE3-EF1-mEGFPI)
(Wissing et al., submitted). As a positive control, an intronless
isogenic construct that encoded an intact eGFP (pLRE3-EF1-mEGFP)
was used. L1 (1 μg) and A3A (200 ng) plasmids were co-transfected
into 293 T cells and the cells were harvested at 2 and 4 days. Similar to
our earlier results (Fig. 5A), at 2 days post-transfection, we observed
minimal (22%) inhibition of the eGFP control plasmid, while rhA3A
had no effect (data not shown). However, the L1 signals we obtained
at 2 days were still very low, which is in line with previous reported
data (Kroutter et al., 2009). By 4 days post-transfection, we observed
detectable L1 retrotransposition (Fig. 11A). As expected, hA3A
potently inhibited L1 retrotransposition. In contrast, rhA3A, as well
as the rhA3AΔSVRmutant, had no effect (Fig. 11A). The effect of hA3A
on L1 retrotransposition could be partially attributed to foreign DNA
restriction, since at 4 days post-transfection, we observed a 2-fold
reduction in eGFP signal from the control plasmid (Fig. 11B).
However, it should be noted that substantial eGFP signals were still
detected, in contrast to near-complete inhibition of L1 by hA3A
(Fig. 11A). Importantly, under conditions where we detected
signiﬁcant foreign DNA restriction by hA3A, no such activity was
observed for rhA3A and rhA3AΔSVR. Thus, we conclude that unlike
hA3A, rhA3A does not restrict L1 retrotransposons and/or foreign
DNA.
Discussion
SIV and SHIV infections of rhesus macaques have been used
extensively as models for studying HIV pathogenesis and in vaccine
development. The fact that the dose, timing and route of infection can
Fig. 11. RhA3A does not inhibit retrotransposition. One microgram of L1 constructs containing eGFP with or without the γ-globin intron in the opposite orientation and 200 ng of
empty vector, hA3A, rhA3A or rhA3AΔSVR plasmid were co-transfected into 293 T cells using Fugene 6 (Roche). At 4 days post-transfection, cells were harvested and analyzed for
eGFP expression using a FACSCalibur machine (BD Biosciences) with 150,000 events. Panel A. Results of co-transfection of LINE 1 plasmid (with intron) with either the empty vector,
hA3A or rhA3A plasmids. To minimize autoﬂuorescence background, the percentage of eGFP+ cells from the untransfected control was gated against an empty ﬂuorescence channel
(FL3). Panel B. Results of co-transfection of eGFP control plasmid (no introns) with either the empty vector, hA3A or rhA3A plasmids.
36 K. Schmitt et al. / Virology 419 (2011) 24–42be controlled also makes it ideal for investigating the earliest events
following pathogenic lentivirus infection, including innate immune
responses. Recent discoveries have shown that speciﬁc lentivirus
genes could antagonize the effects of host innate restriction factors.
Thus, the macaque/SIV or SHIV models provides a compelling system
to explore how these restriction factors are regulated in vivo following
lentivirus infection.
Identiﬁcation of rhA3A as a novel lentiviral restriction factor
TheAPOBEC3 family of deoxycytidinedeaminases function aspotent
antiretroviral factors. Incorporation of select A3 proteins can inhibit
reverse transcription and/or induce G-to-A hypermutation in nascentreverse transcripts in the next target cell (Bishop et al., 2004; Celico
et al., 2006; Russell et al., 2009; Sova and Volsky, 1993; von Schwedler
et al., 1993; Zhengand Peterlin, 2005). SevenA3genes are encoded in the
human genome, but only a subset, hA3G, and to a lesser extent, hA3F and
hA3C, are expressed inCD4+T cells, inhibit HIV-1 and are counteractedby
the HIV-1 encoded Vif protein (Koning et al., 2009; Refsland et al., 2010).
There is uncertaintywhether a similar complement of A3 genes is present
in rhesus macaques, particularly since no rhA3A gene has yet to be
identiﬁed. In this study,we cloned the rhA3Agene. This result is consistent
with a recent study that revealed evolutionary conservationofA3A among
hominids, Old World and NewWorld monkeys (Bulliard et al., 2011). In
addition, analysis of the rhesus macaque genome provided evidence of
seven encoded A3 members that based on phylogenetic analyses are
37K. Schmitt et al. / Virology 419 (2011) 24–42orthologous to the corresponding hA3 genes. These ﬁndings suggest that
the seven rhA3 genes have been maintained after the evolutionary split
between monkeys and humans. Thus, the vif genes of various SIV strains
naturally infecting Old World monkey species have likely been co-
evolving with the same set of A3 genes for millions of years.
Rhesus macaque A3G is a potent A3 deaminase against SIV, SHIV and
HIV-1 (Schmitt et al., 2010; Virgen and Hatziioannou, 2007; Zennou and
Bieniasz, 2006). We therefore determined the expression of the other
rhesus macaque A3 genes in primary, activated CD4+ T cells, the main
cellular targets of SIV and SHIV in vivo, in relation to rhA3G. Our results
indicate that rhA3B mRNA is not expressed and that rhA3D mRNA is
expressed at levels that are likelynot biologically relevant in vivo.RhA3F is
expressed at 2-fold lower levels than rhA3G, but rhA3F appears to be
incorporated promiscuously into virions and is not as functional as rhA3G
in side-by-side co-transfection studies (Schmitt et al., 2010). Only rhA3A,
rhA3C and rhA3H are expressed at similar or higher levels than rhA3G.
RhA3H has been previously shown to have potent antiretroviral activity
against HIV-1 (OhAinle et al., 2008) and we found signiﬁcant activity
against SHIV (unpublished data). We also found no signiﬁcant antiviral
activity of rhA3C against SHIV. Surprisingly, rhA3A exhibited potent
antiretroviral activity. Based on this data,we conclude that rhA3A, rhA3G,
and rhA3H most likely are the dominant rhesus macaque APOBEC3
deaminases that could restrict SHIV or SIV in vivo.
Insights on rhA3A restriction of lentiviruses
Rhesus macaque A3G inhibits SHIVΔvif and HIV-1Δvif virion
infectivity through a mechanism that involves virion incorporation.
Virion incorporated rhA3Gblocks reverse transcription and/or inducesG-
to-A hypermutation in the next target cell. Consistent with this
mechanism, we readily detected rhA3G in SHIVΔvif and HIV-1Δvif
virions, and observed substantial G-to-Amutations in reverse transcripts
newly formed in target cells. Given these consistent phenotypes, we used
rhA3G as a positive control for evaluating the antiretroviral activity of
rhA3A. In this study, we found that rhA3A is as potent as rhA3G in
restricting virus infectivity. Bothproteins inhibited SHIVΔvif infectivity by
approximately 20-fold. In addition, rhA3A modestly inhibited HIVΔvif
infectivityby about3-fold.We found that in contrast to rhA3G, rhA3Awas
incorporated at low levels into SHIVΔvif virions and was undetectable in
HIVΔvif virions (Figs. 6B and D). The results may be due to the sensitivity
of the Western blots and that rhA3A is incorporated into virions at very
low levels compared to rhA3G. This would also suggest that rhA3A
enzymatic activity may be higher than rhA3G on a per-molar basis.
As a ﬁrst step in gaining mechanistic insights on rhA3A-mediated
restriction of SHIV and HIV-1, we evaluated whether two rhA3A
domains are critical for restriction. Comparison of the amino acid
sequences of human and rhesus macaque A3A reveals a monkey-
speciﬁc insertion at positions 27–29 (SVR) that is critical for SHIVΔvif
andHIV-1ΔVif inhibitionby rhA3A thatwas lost in the hominid lineage
(Fig. 1A). In a recentmodeling study of hA3A, it was shown that amino
acids 29 and 30 likely form part of a polynucleotide accommodating
groove near the active-site pocket (Bulliard et al., 2011). We observed
that the rhA3A ΔSVR mutant is totally inactive, while remaining
sensitive to SHIV and HIV-1 Vif-dependent degradation. In addition,
we made just the opposite mutation, the addition of the SVR motif to
hA3A. We found that this mutant gained partial activity against HIV-
1Δvif but was not as active as rhA3A, suggesting that other amino acid
substitutions are likely involved in this function.We also determined if
the canonical cytidine deaminase Zn+2 binding domain (C/H-X-E-X23-
28-P-C-X2-4-C) was critical for rhA3A anti-lentiviral activity. Mutation
of the histidine at position 70 to glutamic acid resulted in no restriction
of SHIVΔvif (unpublished data). Thus, the monkey-speciﬁc residues
SVR (27–29) and the canonical Zn+2 binding domain are critical for
rhA3A-mediated Δvif lentivirus restriction.
Human A3A is largely inactive against HIV-1ΔVif, but when
targeted to the viral nucleocapsid, it has potent activity against HIV-1ΔVif (Goila-Gaur et al., 2007). Since hA3A and the C-terminal region
of hA3G are derived from a common ancestor, the N-terminal domain
of hA3G was fused to hA3A (hA3G-A3A). This hA3G-A3A fusion
protein localized to the cytoplasm, incorporated into the viral
nucleoprotein complexes, and inhibited HIV-1 replication (Goila-
Gaur et al., 2007). Similarly, fusion of hA3A to the Vpr protein resulted
in its incorporation into viral nucleoprotein complexes and inhibition
of HIV-1 and SIV replication (Aguiar et al., 2008). These results
suggested that the reason that hA3A could not restrict lentiviruses is
that it could not be targeted to the virion core. While hA3A had no
substantial activity against HIV-1ΔVif, hA3A surprisingly decreased
SHIVΔVif virion infectivity by approximately 10-fold. Althoughwe did
not detect hA3A in virions, it is possible that like rhA3A, very little is
incorporated into nascent virions and is below the limits of detection
by Western blot analysis.
Evidence for recent evolutionary gain of function of DNA restriction in
hominids
Previous studies have shown that while hA3A is inactive against
HIV-1, it can block endogenous retroviral elements such as LTR-
retrotransposons or Alu elements (Bogerd et al., 2006b; Chen et al.,
2006). Human A3A has antiviral activity against autonomous (minute
virus of mice; MVM) and non-autonomous (AAV-2) replicating
parvoviruses and has editing activity against the human papilloma-
virus genome (Chen et al., 2006; Narvaiza et al., 2009; Vartanian et al.,
2008). Finally, hA3A has been shown to counteract foreign DNA
(Stenglein et al., 2010) and promote DNA damage (Landry et al.,
2011). These studies suggest that hA3A biology is intimately linked to
the restriction of double-stranded DNA elements. Surprisingly, we
found no evidence for rhA3A restricting AAV-2, L1 elements and
foreign DNA. While it can be argued that rhA3A may have an activity
against rhesus macaque AAV, no infectious macaque AAVs have been
isolated to date. Thus, the DNA restriction properties of A3A may have
been a recent evolutionary development in the hominid lineage.
Themammalian A3 locus encodes genes that have among the highest
detectable evolutionary pressures known (Sawyer et al., 2004). This is
thought to reﬂect a long-standing host-pathogen genetic conﬂict that
eventually helps dictate current trends in cross-species transmission and
viral host range. Our ﬁndings now enter A3A into this select group of
genes, given the divergent virus speciﬁcities of the human and monkey
homologues. RhA3A inhibits theSHIVΔvifandHIV-1ΔVif, butnot theDNA
virus AAV-2 and L1 retroelements, while hA3A inhibits SHIVΔvif, AAV-2
and L1 elements but not HIV-1 Δvif. Thus, it would appear that rhA3A
could inhibit a broader range of lentiviruses at the cost of having no
activity against DNA viruses. On the other hand, hA3A appears to have
acquired activity against DNA viruses, at the expense of losing broad
potency against lentiviruses. The rhA3A mutant with amino acids 27–29
deleted (rhA3AΔSVR) was incapable of restricting SHIVΔvif and HIV-
1Δvif. Thus, the divergent viral speciﬁcities of hA3A and rhA3A may be
dictated, at least in part, by an evolutionary switch that involved
alterations in the polynucleotide-binding groove of A3A. The 81% identity
between hA3A and rhA3A at the amino acid level should enable
structure-based domain-swap experiments to determinewhich residues
account for differential virus restriction. These types of studies should
provide abiologically relevant systemto interrogatewhich changes in the
molecular determinants of nucleic acid speciﬁcity of the A3A proteins
dictates the antiviral activity of A3Aagainst lentiviruses, parvoviruses and
L1 retroelements.
Materials and methods
Cells, viruses, and plasmids
HeLa and 293 cells were used for transfections of vectors
expressing various APOBEC3 proteins, full-length SHIV or HIV-1
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measure the infectivity of viruses (Derdeyn et al., 2000; Platt et al.,
2009; Takeuchi et al., 2008; Wei et al., 2002). Both cell lines was
maintained in Dulbecco's minimal essential medium (DMEM) with
10% fetal bovine serum (R10FBS), 10 mM Hepes buffer, pH 7.3, and
100 U/μg penicillin-streptomycin and 5 μg gentamicin. Rhesus ma-
caque PBMCs were obtained from uninfected animals and isolated on
Ficoll/Hypaque gradients. The derivation of SHIVKU-2MC4 (a pathogenic
molecular clone; referred to in the text as SHIV) and SHIVVifSTOP
(referred to in the text as SHIVΔvif) has been previously described
(Liu et al., 1999; Schmitt et al., 2010). A plasmid with the genome of
HIV-1 strain NL4-3 (referred to in the text as HIV-1) was used to
construct a Δvif version (referred to in text as HIV-1Δvif) (pNL4-3;
NIH AIDS Research and Reference Reagent Program). This plasmid
was digested with PﬂM1, phenol:chloroform extracted, and ethanol
precipitated. The 5′-protruding ends were ﬁlled using DNA Polymer-
ase I Large Fragment (Klenow; Promega). The resulting Klenow
fragment reaction produced blunt ended fragments that were puriﬁed
and re-ligated. The resulting plasmid was sequenced and found to
contain a deletion in pNL4-3 vif between base pairs 5301 to 5308.
Therefore, only the ﬁrst 79 amino acids of pNL4-3 Vif could be
expressed. The plasmids pcDNA3.1(+)-HA-rhA3G and pcDNA3.1(+)-
HA-hA3A were kindly provided by Nathaniel Landau (New York
University School of Medicine). A plasmid expressing HA-rhA3C was
constructed in this laboratory and cloned into the pCruz-HA vector
(Santa Cruz Biotechnology) using restriction sites Sca I and Kpn I. A
plasmid expressing pcDNA3.1(+)-HA-hA3G used in these studies was
provided by the NIH AIDS Reference and Reagent Program.Molecular cloning of rhA3A
Total RNA from mitogen-activated rhesus macaque PBMCs was
isolated using the RNAEasy Kit (QIAGEN; Valencia, CA). Three hundred
nanogramof samplewas subjected to randomhexamerprimingusing the
RT2EZﬁrst strandkit (SABiosciences), and4 μl of this cDNAwas subjected
to a 40 μl PCR reaction consisting of 1x Sweet PCR Mix (SA Biosciences),
12.5 pmol of rhA3A.F (5′-GACAAGCACATGGACGGCAG) and rhA3A.R (5′-
CATCCTTCAGTTTCCCTGAT) primers, designed based on the ﬁrst and last
exons of human A3A (hA3A). Ampliﬁcation conditions included 95 °C for
15 min hot-start, followed by 40 cycles at 94 °C 30 s, 50 °C 30 s and 72 °C
3 min in a PE 9700machine (Perkin Elmer). A dominant PCR amplicon of
600 bp was subcloned into the TOPO-TA vector (Invitrogen) and
sequenced. The sequence for rhesusmacaqueA3A (rhA3A)was submitted
to GenBank with Accession number JF831054. An expression construct
containing rhA3A linked to an N-terminal HA-tag was synthesized
(GenScript). The HA-rhA3A genewas subcloned into pcDNA3.1(+) using
restriction sites Kpn I and Eco RV of pcDNA3.1(+) and sequence-
conﬁrmed.Positioning of rhA3 genes in the rhesus macaque genome
Analysis of the Apobec3 loci was performed using NCBI Build 1.2
version of the macaque chromosome 10 sequence. RhA3C (Accession
# EU381233), rhA3G (XM_001094452), rhA3F (DQ514917) and rhA3H
(DQ507277) cDNA sequences were subjected to BLAST analysis
against the macaque genome, and the corresponding coordinates
were obtained. To characterize the intronic sequence ﬂanked by exons
1 and 2 of rhA3A, exon 1 (5′-AGAAGAGACAAGCACATGGAC) and exon
2 (5′-GCTCCACCTCGTAGCACAA) speciﬁc primers were used to
directly amplify rhesus macaque genomic DNA. The resulting PCR
amplicon was directly sequenced (Fig. 2; see text for details). RhA3B
and rhA3D sequences were predicted based on the genome sequences
upstream of rhA3C and between rhA3C and rhA3F, respectively, using
the geneid program (http://genome.crg.es/geneid.html).Phylogenetic analysis of rhApobec3A
The A3A amino acid sequences from various primate species were
obtained from Bulliard et al. (2011). Sequences were aligned using
ClustalX using the Gonnet series, and neighbor-joining trees were
constructedwith1000 subreplicates, correcting formultiple substitutions
and excluding gaps. The C-terminal half of rhA3G was used as an
outgroup. A3 amino acid sequences from human, mouse, rat and rhesus
macaque were likewise aligned using Clustal X, after splitting the
sequences of rodent A3 and primate A3B, A3DE, A3F and A3G into N-
terminal and C-terminal halves. Neighbor-joining trees were performed
unrooted, with 1000 subreplicates and excluding gaps.
Expression of rhA3A in rhesus macaque tissues
A rhesusmacaque that has been euthanized and perfusedwith 2 l of
Ringer's saline to remove contaminating bloodwas used to examine the
expression of rhA3A mRNA in different tissues (visceral organs and
brain). RhA3Awas ampliﬁed from 30 μg of each visceral and CNS tissue
using the RNAEasy kit (Qiagen, Valencia, CA). RNA was digested with
1 U/μl DNase-I (Fermentas) for 30 min. RT-PCRwasperformedusing the
Titan One RT-PCR kit (Roche). Each reaction used 100 ng of total RNA
andwas ampliﬁed using oligonucleotide primers speciﬁc for rhA3A. The
oligonucleotides used for the reverse transcriptase reaction and ﬁrst
round PCR were 5′-GGACGGCAGCCCAGCATCCAGGCCCAG-3′ (sense)
and 5′-CGTAGGTCATGATGGAGACTTGGGC-3′ (antisense), which are
complementary to bases 3–29 and 451–475, respectively. The nested
oligonucleotides used were 5′-CCAGGCCCAGACACTTGATGGATCC-3′
(sense) and 5′-CCGCAGCGTTCGCAGTGCCTCCTGATACAGG-3′ (anti-
sense), which are complementary to bases 20–44 and 411–441,
respectively. As a control, GAPDH was ampliﬁed to verify the integrity
the RNA using oligonucleotides 5′-GCCATCACTGCCACCCAG-3′ (sense)
and 5′-GCCACATACCAGGAAATGAGC-3′ (antisense). The nested oligo-
nucleotides used were 5′-CCTCCGGGAAACTGTGGC-3′ (sense) and 5′-
CGTTGAGGGCAATGCCAG-3′ (antisense). The reactionswere performed
in anABI 2720 Thermal Cycler using the following thermal proﬁle: 42 °C
30 min for 1 cycle; 94 °C 2 min for 1 cycle, 94 °C 30 s, 55 °C 30 s, and
68 °C 45 s for 10 cycles; 94 °C for 30 s, 55 °C 30 s, and 68 °C 2 min for 25
cycles. Onemicroliter of the initial reactionmixturewas used for nested
PCRusing rTaq (Takara) andperformedwith the following thermal cycle
proﬁle: 95 °C for 1 min, 48 °C 2 min, and 72 °C 3 min for 35 cycles. The
450 bp amplicon was visualized in a 1.5% agarose gel, excised and gel
puriﬁed (Qiagen, Valencia, CA) and directly sequenced.
Expression of rhA3 genes in activated CD4+ T cells
Rhesus PBMCs were obtained from three donors by Ficoll
separation. 5×106 cells were seeded into each well of a 6-well plate
containing 3 ml RPMI medium (Mediatech) with 10% Fetal Bovine
Serum (Gemini Biosciences). Half of the cultured PBMCs were
activated with 2.5 μg/ml Staphylococcal Enterotoxin B (SEB; Toxin
Technology) overnight. The following day, the PBMCs were stained
with CD3-V450 (clone SP34-2), CD4-APC-H7 (L200) and CD25-PerCP-
Cy5.5 (M-A251) (BD Biosciences) and analyzed in an LSR-II ﬂow
cytometer (BD Biosciences). Histogram plots to highlight CD25
expression in CD4+ T cells were constructed using the FlowJo
software (Treestar). CD4+ T cells were puriﬁed from activated
PBMCs by negative selection with magnetic beads (Miltenyi Biotec).
Total RNAwas extracted from CD4+ T cells using the RNAEasy kit, and
cDNA was synthesized by random hexamer priming using the RT2 EZ
ﬁrst strand kit (SA Biosciences). The cDNAwas used for triplicate real-
time PCR evaluations (25 μl) with optimized A3-speciﬁc primers and a
housekeeping gene, GAPDH, in a BioRad real-time PCR machine.
Brieﬂy, 5 μl of cDNA was mixed with 12.5 μl of 1× Universal Master
Mix (Applied Biosystems), 10 pmol of primers and 5 pmol of probe
and subjected to 40 cycles of denaturation and annealing/elongation.
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Table 1. Cloned cDNA sequences were used as standards and for
evaluating cross-reactivity (Table 2). The A3-speciﬁc assays had a
limit of detection of 5 copies per reaction, and standard curves had r2
valuesN98%.Subcellular localization of rhA3A
For intracellular localization of rhA3A, 293 cells were plated onto
13 mm cover slips in a 6 well plate and transiently co-transfected with
vectors expressing HA-tagged hA3A, rhA3G or rhA3A and one
expressing a eGFP tagged nuclear marker using a polyethylenimine
(PEI) transfection reagent (ExGen™ 500, MBI Fermentas) according to
the manufacturer's instructions. Cultures were maintained for 36–48 h
before beingwere ﬁxed in 2%paraformaldehyde for 10 min andwashed
twice for 5 min in 1x PBS (pH7.4). Cover slips were incubated with a
rabbit polyclonal anti-HA antibody (HA-probe, Santa Cruz) for 1 h at
ambient temperature in 1x PBS plus 1% BSA. Cover slips were washed
twice for 5 min in PBS and reacted with a Cy-5 conjugated secondary
antibody (Abcam) 1x PBS plus 1% BSA for 30 min. The cover slips were
washed twice for 5 min in 1x PBS and mounted in glycerol containing
mountingmedia (Slowfade antifade solution A, Invitrogen). A Nikon A1
confocal microscope was used to collect 100× images with a 2× digital
zoom, using EZ-C1 software. The pinhole was set to large for all
wavelengths used with Cy5 and eGFP excited using a 638 nm and
488 nmdiode lasers, respectively. Imageswere collectedusinga670 nm
ﬁlter for Cy5 and 525/25 nm ﬁlter for eGFP.Foreign DNA restriction by rhA3A
293 cells were seeded into 6-well tissue culture plates 24 h prior to
transfection. Cells were ﬁrst transfected with 3 μg of either HA-rhA3A,
HA-hA3A, HA-rhA3G HA-rhA3AΔSVR or pcDNA3.1(+) vector using a
polyethylenimine transfection reagent (ExGen™ 500, MBI Fermentas)
according to themanufacturer's instructions. After 24 h, the cellswere re-
transfectedwith 3 μg of a vector expressing eGFP. Cells were incubated at
37 °C in 5%CO2 atmosphere for either 2 or 5 days. The cellswere removed
from the plate using Ca2+/Mg2+−free PBS containing 10 mMEDTA. Cells
were then ﬁxed in 2% paraformaldehyde, for 5 min. The cells were
washed twice in 1x PBS plus and analyzed using an LSRII ﬂow cytometer.
The mean ﬂuorescence intensity (MFI) for eGFP positive cells was
calculated. The MFI ratio and percentage of eGFP positive cells were
calculated for each sample. Normalized ratios from three separate
experimentswere averaged and the standard error calculated. All groups
were compared to pcDNA3.1(+) plus eGFP control using a Student's t-
test with pb0.05 considered signiﬁcant.Production of SHIVΔVif virions in the presence of A3A
293 cells were seeded into a 12-well tissue culture plate 24 h prior to
transfection. Cells were ﬁrst transfected with 0.5 μg of HA-tagged rhA3A,
hA3A, rhA3G or pcDNA3.1(+) vector using PEI (Fermentas). After 24 h,
cells were transfected with 1 μg of SHIVΔVif or HIV-1Δvif plasmid. Cells
were incubated at 37 °C in 5% CO2 atmosphere for 48 h. Supernatants
were collected and cellular debris removed by low speed centrifugation.
The cells were lysed in 500 μl of RIPA (50 mM Tris–HCl, pH 7.5, 50 mM
NaCl, 0.5% deoxycholate, 0.2% SDS, 10 mM EDTA) and the nuclei were
removed through high speed centrifugation. The amount of Gag p27 or
p24present in the viral supernatantswasmeasuredusing a commercially
available p27 and p24 ELISA kits (ZeptoMetrix). The experiment was run
at least three separate times, normalized to the empty vector control
samples. Differences betweenmean percentages were calculated using a
two-tailed Student's t-test with pb0.05 considered signiﬁcant.Inhibition of SHIV and HIV-1 virion infectivity by A3A
SHIV, SHIVΔVif, HIV-1 or HIVΔVif infectious molecular clones
(3 μg) were co-transfected (0.5 μg) with plasmids expressing rhA3A,
rhA3G, rhA3C, hA3A, or hA3G using PEI (Fermentas) in a 6-well plate.
At 48 h post-transfection, the culture medium was harvested and
clariﬁed by low speed centrifugation. Equivalent amounts of p27 were
serially diluted using 10-fold dilutions from 101 to 106 and used to
inoculate TZM-bl cells. At 48 h post-inoculation, the media was
removed, cells washed with PBS and the monolayer ﬁxed using 1%
formaldehyde–0.2% glutaraldehyde in PBS. The cells were washed and
incubated in a solution for 2 h at 37 °C containing 4 mM potassium
ferrocyanide, 4 mM potassium ferricyanide, 4 mM magnesium chlo-
ride, and 0.4 mg X-gal per ml. The reaction was stopped and the
infectious units (IU) per ml were calculated (Derdeyn et al., 2000;Wei
et al., 2002).Site-directed mutagenesis
Mutations introduced into all plasmids were accomplished using a
QuikChange site-directed mutagenesis kit (Stratagene) according to
the manufacturer's protocol. All plasmid inserts were sequenced to
ensure the validity of the mutations and that no other mutations were
introduced during the cloning process.Virion incorporation assays
SHIV, SHIVΔVif, HIV-1 or HIVΔVif infectious molecular clones
(3 μg) were co-transfected with 1.5 μg of plasmids expressing either
rhA3A, rhA3G, hA3G or hA3A proteins into 293 cells using PEI reagent
(Ex-Gen™ 500, Fermentas) in each well of a 6-well plate. At 48 h,
virus supernatants were harvested and clariﬁed by low speed
centrifugation. The clariﬁed supernatant was ultracentrifuged to
pellet virions (SW41 rotor, 247,000×g, 1 h, 4 °C). The pellet was
resuspended in PBS and layered on a 20%/60% sucrose step gradient
and again subjected to ultracentrifugation (SW55Ti, 247,000×g, 1 h)
at 4 °C. The interface (containing virions) was harvested, pelleted
again by ultracentrifugation as described above, and resuspended in
150 μl of PBS. An aliquot was saved to determine the p27 or p24
content by antigen capture assay (ZeptoMetrix). The remaining
sample was boiled in 2× sample reducing buffer. Equivalent amounts
of p27 or p24 were loaded on a 12% SDS-PAGE gel. A3 proteins were
detected by Western blotting using an anti-HA antibody (HA-probe;
Santa Cruz). Blots were placed in stripping buffer (25 mM glycine, pH
2.0 and 1% SDS) and reprobed using either rabbit polyclonal antibody
speciﬁc for p27 or a mouse monoclonal antibody to p24 (NIH AIDS
Research and Reference Reagent Program).Stability of rhA3A in the presence of SHIV and HIV-1 genomes
Infectious molecular clones of HIV-1, HIV-1Δvif or SHIV and SHIVΔvif
were co-transfected in a 2:1 ratio with rhA3A, rhA3G, hA3G, hA3A, or
rhA3AΔSVR using PEI transfection reagent (Ex-Gen500; Fermentas) into
a 12-well plate. At 24 h post-transfection, the supernatant was removed,
the cells were harvested and lysed using RIPA buffer. Following lysis, the
nuclei were removed by centrifugation at 14,000 rpm for 15 min in a
microfuge at 4 °C. The protein was precipitated using methanol,
resuspended in 2× sample reducing buffer, and boiled for 5 min. Proteins
were separated on a 12% SDS-PAGE gel and probed using commercially
available rabbit polyclonal HA antibody (HA-probe, Santa Cruz). All
samples were normalized to the same amount of β-actin protein using a
mouse monoclonal antibody speciﬁc for β-actin (AC15; Novous
Biologicals).
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Todeterminewhether virion-incorporated rhA3A can induceG-to-A
mutations in nascent reverse transcripts, 293 cells were co-transfected
with vectors containing the genomes SHIV or SHIVΔVif and vectors
expressing rhA3G (positive control), rhA3C (negative control) or rhA3A
using PEI (Fermentas). At 24 h post-transfection, cells werewashed and
fresh DMEM was added. At 48 h, the supernatant containing virus was
subjected to ultracentrifugation through a 20% sucrose cushion. The
resulting supernatant was DNase-I-treated (Fermentas) at 37 °C for
30 min to minimize plasmid carry-over. Infectious titers in the
supernatants were measured on TZM-bl cells. At 24 h post-infection of
TZM-bl cells, total cellular DNA was harvested and extracted using the
DNeasy kit (Qiagen). The DNAwas used in a nested DNA PCR to amplify
a 300 base pair fragment of nef. The PCR reaction was carried out using
rTaq and themanufacturer's instructions (Takara). The oligonucleotides
employed during in the ﬁrst round PCR to amplify SIV nef were 5′-
GGTGGAGCTATTTCCATGAGG-3′ (sense) and 5′-GTCTTCTTGGACTG-
TAAT AAATCCC-3′ (anti-sense). One microliter of the ﬁrst PCR product
was added to a nested reaction. The oligonucleotides used during the
nested PCR reaction were 5′-CCATGAGGCGGTCCAGGCAGTCTAGAG-3′
(sense) and 5′-CCTCCCAGTCCCCCCT TTTC-3′ (anti-sense). The PCR
reactions were performed using an ABI 2720 Thermal Cycler with the
following thermal proﬁle: 95 °C for 2 min, 1 cycle; 95 °C for 30 s, 55° for
30 s, 65 °C for 2 min, for 35 cycles; 65 °C for 7 min. The PCRproductswere
separated by electrophoresis, isolated, puriﬁed, sequenced and sub-
cloned into pGEM-TEasy (Promega). Fifteen independent clones were
sequenced and assessed for eachmutant SHIV as described above for each
condition.
Adeno-associated virus-2 (AAV-2) replication assay
The ability of rhA3A to inhibit the replication of AAV2 was assessed.
293 cells were transfected using LipoD 293 transfection reagent
(SignaGen Labs;, Rockville, MD) into 60 mm dishes in duplicate with
1 μg SSV9 (an AAV2 infectious clone, psub201) (Qiu and Pintel, 2002),
2 μg pHelper (Stratagene, La Jolla, CA) (Xiao et al., 1998), and 1 μg of an
A3 expression vector, rhA3G, hA3A, rhA3A, or as a negative control
pBluescript SK (+) (Stratagene, La Jolla, CA). Forty-eight hours post-
transfection, the cells were harvested and resuspended in PBS. The
supernatant was discarded and Hirt DNA was extracted using Hirt
solution (10 mM Tris, 10 mM EDTA, pH 7.5, 0.6% SDS) at room
temperature for 10 min followed by 5 M NaCl at 4 °C overnight. The
mixture was centrifuged at 14,000 rpm at 4 °C for 20 min. Following
centrifugation, the pellet was discarded and the supernatant was
treatedwith Proteinase K (50 μg/ml) at 37 °C for 1 h. The lowmolecular
weight (LMW) DNA was extracted twice with saturated phenol and
once with chloroform/isoamyl alcohol. The resulting DNA was ethanol
precipitated and column puriﬁed using the Qiagen gel extraction kit
(Qiagen). The LMW DNA was run on a 1% agarose gel, transferred to
nitrocellulose and analyzed by Southern hybridization using a
32
P-
labeled probe consisting of a fragment representing nucleotides 184–
4490 (Xba I digestion) from SSV9 as previously described (Qiu and
Pintel, 2002). To ensure that all sampleswere expressing the desired A3
proteins, aliquots of harvested cells utilized in the Southern blot were
lysed in RIPA buffer. The nuclei were removed and the protein was
precipitated usingmethanol, resuspended in 2×sample reducingbuffer,
and boiled for 5 min. Proteins were separated on a 12% SDS-PAGE gel
andprobedusing a rabbit polyclonal anti-HAantibody (HA-probe, Santa
Cruz).
L1 retrotransposition assay
The engineered L1 enhanced green ﬂuorescent protein (EGFP)
reporter (Ostertag et al., 2000) was cloned into the pLRE3-EF1-mEGFPI,
which contains a retrotransposition competent L1 element (LRE3)(Brouha et al., 2003) under the control of an EF-1α promoter in
addition to the internal 5′ UTR promoter. The enhanced GFP (eGFP)
retrotransposition indicator cassette is under the control of an
ubiquitin promoter (UBC), and the SV40 late polyadenylation signal.
The construct was cloned into pBSKS-II+ (Stratagene). The positive
control pLRE3-EF1-mEGFP(Δintron) is similar to the pLRE3-EF1-mEGFPI
but lacks the intron in the mEGFPI indicator cassette and therefore
serves as a positive control for transfection efﬁciency. One microgram
of L1 construct and 200 ng of empty vector, hA3A, rhA3A or
rhA3AΔSVR plasmid were co-transfected into 293 T cells using
Fugene 6 (Roche). All transfections were performed in triplicate.
Cells were harvested at 2 and 4 days and analyzed for eGFP expression
using a FACSCalibur machine (BD Biosciences), collecting 150,000
events.
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